Dr. Naylor’s clinical and research expertise are in genetic and atypical forms of diabetes. She is a co-Investigator of the US National Monogenic Diabetes Registry housed at the University of Chicago, an investigator of the rare and atypical diabetes network, or RADIANT study and contributes to the American Diabetes Association Precision Medicine in Diabetes Initiative. Her work addresses barriers to accurate genetic diagnosis of MODY and inequities in who benefits from diabetes precision medicine. She has carried out cost-effectiveness analyses demonstrating the economic value of accurate genetic diagnosis of MODY and ongoing studies seek to clarify best management practices for MODY and support broader implementation of precision medicine in diabetes.
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series.
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Res Care. 2025 Apr 23; 13(2).
PMID: 40274278
Advancing Monogenic Diabetes Research and Clinical Care by Creating a Data Commons: The Precision Diabetes Consortium (PREDICT).
Advancing Monogenic Diabetes Research and Clinical Care by Creating a Data Commons: The Precision Diabetes Consortium (PREDICT). J Diabetes Sci Technol. 2025 Jan 09; 19322968241310896.
PMID: 39781649
Precision treatment of beta-cell monogenic diabetes: a systematic review.
Precision treatment of beta-cell monogenic diabetes: a systematic review. Commun Med (Lond). 2024 Jul 18; 4(1):145.
PMID: 39025920
High Prevalence of A-ß+ Ketosis-Prone Diabetes in Children with Type 2 Diabetes and Diabetic Ketoacidosis at Diagnosis: Evidence from the Rare and Atypical Diabetes Network (RADIANT).
High Prevalence of A-ß+ Ketosis-Prone Diabetes in Children with Type 2 Diabetes and Diabetic Ketoacidosis at Diagnosis: Evidence from the Rare and Atypical Diabetes Network (RADIANT). Pediatr Diabetes. 2024; 2024.
PMID: 38765897
Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country.
Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country. Popul Med. 2024 Mar; 6.
PMID: 38681897
Investigator and participant expectations for returning non-genetic results: insights from the Rare and Atypical Diabetes Network (RADIANT) study.
Investigator and participant expectations for returning non-genetic results: insights from the Rare and Atypical Diabetes Network (RADIANT) study. J Clin Transl Sci. 2023; 7(1):e260.
PMID: 38229892
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023 Oct; 29(10):2438-2457.
PMID: 37794253
Systematic Review of Treatment of Beta-Cell Monogenic Diabetes.
Systematic Review of Treatment of Beta-Cell Monogenic Diabetes. medRxiv. 2023 Sep 22.
PMID: 37214872
Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY).
Objective and Subjective Sleep Patterns in Adults With Maturity-Onset Diabetes of the Young (MODY). Diabetes Care. 2023 03 01; 46(3):608-612.
PMID: 36637968
Enrollment of underrepresented racial and ethnic groups in the Rare and Atypical Diabetes Network (RADIANT).
Enrollment of underrepresented racial and ethnic groups in the Rare and Atypical Diabetes Network (RADIANT). J Clin Transl Sci. 2023; 7(1):e47.
PMID: 36845305